ATE541038T1 - Verwendung eines phagen mit anzeige eines peptids eines adhäsionsproteins zur behandlung einer erkrankung im zusammenhang mit intrazellulärer bildung von fibrillären proteineinschlüssen oder aggregraten - Google Patents

Verwendung eines phagen mit anzeige eines peptids eines adhäsionsproteins zur behandlung einer erkrankung im zusammenhang mit intrazellulärer bildung von fibrillären proteineinschlüssen oder aggregraten

Info

Publication number
ATE541038T1
ATE541038T1 AT07799710T AT07799710T ATE541038T1 AT E541038 T1 ATE541038 T1 AT E541038T1 AT 07799710 T AT07799710 T AT 07799710T AT 07799710 T AT07799710 T AT 07799710T AT E541038 T1 ATE541038 T1 AT E541038T1
Authority
AT
Austria
Prior art keywords
aggregates
protein
peptide
inclusions
treatment
Prior art date
Application number
AT07799710T
Other languages
English (en)
Inventor
Beka Solomon
Noa Sharon
Oded Grinstein
Original Assignee
Univ Ramot
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Ramot filed Critical Univ Ramot
Application granted granted Critical
Publication of ATE541038T1 publication Critical patent/ATE541038T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/14011—Details ssDNA Bacteriophages
    • C12N2795/14111—Inoviridae
    • C12N2795/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/14011—Details ssDNA Bacteriophages
    • C12N2795/14111—Inoviridae
    • C12N2795/14161—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
    • C12N2810/405—Vectors comprising RGD peptide
AT07799710T 2006-07-21 2007-07-19 Verwendung eines phagen mit anzeige eines peptids eines adhäsionsproteins zur behandlung einer erkrankung im zusammenhang mit intrazellulärer bildung von fibrillären proteineinschlüssen oder aggregraten ATE541038T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83222906P 2006-07-21 2006-07-21
PCT/US2007/073858 WO2008011503A2 (en) 2006-07-21 2007-07-19 Use of a phage displaying a peptide from an adhesion protein for treating a disease associated with intracellular formation of protein fibrillar inclusions or aggregates

Publications (1)

Publication Number Publication Date
ATE541038T1 true ATE541038T1 (de) 2012-01-15

Family

ID=38957610

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07799710T ATE541038T1 (de) 2006-07-21 2007-07-19 Verwendung eines phagen mit anzeige eines peptids eines adhäsionsproteins zur behandlung einer erkrankung im zusammenhang mit intrazellulärer bildung von fibrillären proteineinschlüssen oder aggregraten

Country Status (8)

Country Link
US (1) US20090324554A1 (de)
EP (1) EP2054515B1 (de)
JP (1) JP2009544718A (de)
CN (1) CN101553567A (de)
AT (1) ATE541038T1 (de)
AU (1) AU2007275258A1 (de)
CA (1) CA2659032A1 (de)
WO (1) WO2008011503A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5214632B2 (ja) * 2007-12-04 2013-06-19 サッポロビール株式会社 骨吸収抑制剤
WO2009143465A1 (en) * 2008-05-22 2009-11-26 Ramot At Tel Aviv University Ltd. Method of imaging abnormal deposits or plaques
BRPI0921557A2 (pt) * 2008-11-24 2019-09-24 Univ Ramot bacteriófago filamentoso, primeiro e segundo bacteriófago filamentoso para o uso no tratamento do mal de parkinson, composição farmacêutica, e , método para tratar um paciente
CN103476420A (zh) 2011-03-11 2013-12-25 台拉维夫大学拉莫特 用于治疗神经变性tau病的方法
EP2696678B1 (de) * 2011-04-15 2019-11-20 Molecular Transfer, Inc. Mittel zur verbesserten verabreichung von nukleinsäuren in eukaryotische zellen
US20140220660A1 (en) 2011-07-27 2014-08-07 Jason Wright Process for the production of filamentous bacteriophage
US20130084337A1 (en) 2011-08-05 2013-04-04 Neurophage Pharmaceuticals, Inc. Pure filamentous bacteriophage and methods of producing same
EP2785364B1 (de) 2011-11-29 2019-01-09 Proclara Biosciences, Inc. Verwendung von bakteriophagen-p3 als amyloidbindemittel
PT2906235T (pt) 2012-10-02 2017-09-28 Proclara Biosciences Inc Utilização de p3 de proteínas de fusão de bacteriófago como agentes ligantes amilóides
US9988444B2 (en) 2013-05-28 2018-06-05 Proclara Biosciences, Inc. Polypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicity
CN104258372B (zh) * 2014-09-25 2017-01-25 中山大学 Rgd三肽在制备治疗阿尔茨海默症药物中的用途
CN107250154A (zh) 2014-12-03 2017-10-13 普罗克拉拉生物科学股份有限公司 包含缺乏糖基化信号的经修饰的噬菌体g3p氨基酸序列的多肽
CN106800590B (zh) * 2015-11-25 2021-04-09 杭州智鹤丹谷生物医药有限公司 一种结合多种淀粉样蛋白单体和聚集体的多肽及其应用
EP3630153A2 (de) * 2017-05-22 2020-04-08 National Hellenic Research Foundation Makrocyclische modulatoren von krankheitsassoziierter proteinmissfaltung und aggregation
EP3684784B1 (de) * 2017-09-20 2024-03-27 Council of Scientific and Industrial Research Potente peptid-inhibitoren der proteinaggregation
WO2022073127A1 (en) * 2020-10-07 2022-04-14 Tatum Bioscience Inc. Live biotherapeutics secreting synthetic bacteriophages in the treatment of cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040013647A1 (en) * 1999-09-03 2004-01-22 Ramot At Tel-Aviv University Ltd. Methods and compositions for treating a plaque-forming disease
CA2349434A1 (en) * 1999-09-03 2001-03-15 Ramot University Authority For Applied Research & Industrial Development Ltd. Agents and compositions and methods utilizing same useful in diagnosing and/or treating or preventing plaque forming diseases
ES2392247T3 (es) * 2002-03-05 2012-12-07 Ramot At Tel-Aviv University Ltd. Compuesto inmunizante y método para inducir una respuesta inmune contra el sitio de escisión de la beta-secretasa de la proteína precursora de amiloide
WO2006050041A2 (en) * 2004-10-28 2006-05-11 Ramot At Tel Aviv University Ltd. Methods for reducing or inhibiting brain inflammation or for promoting neurogenesis
PL1853285T3 (pl) * 2005-02-01 2011-08-31 Univ Ramot Sposób leczenia zapalenia związanego ze złogami amyloidowymi i zapalenia mózgu z udziałem aktywowanych komórek mikrogleju
WO2006100681A2 (en) * 2005-03-25 2006-09-28 Ramot At Tel Aviv University Ltd. Human synthetic single-chain antibodies directed against the common epitope of mutant p53 and their uses

Also Published As

Publication number Publication date
CN101553567A (zh) 2009-10-07
WO2008011503A2 (en) 2008-01-24
EP2054515A2 (de) 2009-05-06
JP2009544718A (ja) 2009-12-17
WO2008011503A3 (en) 2008-06-26
CA2659032A1 (en) 2008-01-24
EP2054515B1 (de) 2012-01-11
AU2007275258A1 (en) 2008-01-24
US20090324554A1 (en) 2009-12-31

Similar Documents

Publication Publication Date Title
ATE541038T1 (de) Verwendung eines phagen mit anzeige eines peptids eines adhäsionsproteins zur behandlung einer erkrankung im zusammenhang mit intrazellulärer bildung von fibrillären proteineinschlüssen oder aggregraten
Chen et al. Androgens and androgen receptor actions on bone health and disease: from androgen deficiency to androgen therapy
ZA202211057B (en) Anti-trem2 antibodies and methods of use thereof
Gillrie et al. Diverse functional outcomes of P lasmodium falciparum ligation of EPCR: potential implications for malarial pathogenesis
CR20200566A (es) Anticuerpos anti-sirpa y metodos de utilización de los mismos
NZ596409A (en) Anti macrophage migration inhibitory factor antibodies
ATE501723T1 (de) Verfahren zur behandlung von entzündungen in zusammenhang mit amyloid-ablagerungen und hirnhautentzündung unter beteiligung aktivierter mikroglia
PE20110802A1 (es) Un anticuerpo antagonista de pcsk9
NZ594514A (en) Interleukin-17 BINDING PROTEINS
PE20071055A1 (es) Anticuerpos anti mn
AR062065A1 (es) Anticuerpo humanizado
ATE492563T1 (de) Vollständige humane monoklonale antikörper gegen il-13
BRPI0410963B8 (pt) anticorpo que especificamente se liga a uma região no fator de crescimento do tecido conjuntivo humano, anticorpo quimérico, composição farmacêutica, uso de um anticorpo, par de polinucleotídeos, polinucleotídeo recombinante, e, microrganismo
MX357972B (es) Materiales y metodos para el tratamiento o prevencion de enfermedades asociadas al her-3.
BR112012008665A2 (pt) tratamento de câncer
EA201390874A1 (ru) Моноклональное антитело человека со специфичностью к белку e вируса денге серотипа 1 и его применение
PE20140190A1 (es) Moduladores de proteinas notum y metodos de uso
IN2014CN04498A (de)
RU2013126581A (ru) Мутанты стрептокиназы и их ковалентно модифицированные формы
EA201390820A1 (ru) Слитый белок против рака
MX2022007231A (es) Anticuerpos anti-mertk y metodos de uso de los mismos.
MX2021002299A (es) Anticuerpos de anti-cd33 y metodos para usarlos.
CL2023001600A1 (es) Biomarcadores del agonista de trem2 y métodos para su uso
NZ591918A (en) Antibodies to modified human igf-1/e peptides
DE602006012463D1 (de) Konjugat mit p21-protein zur krebsbehandlung